MEP60108A - Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions - Google Patents

Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions

Info

Publication number
MEP60108A
MEP60108A MEP-601/08A MEP60108A MEP60108A ME P60108 A MEP60108 A ME P60108A ME P60108 A MEP60108 A ME P60108A ME P60108 A MEP60108 A ME P60108A
Authority
ME
Montenegro
Prior art keywords
dyslipidemias
treating atherosclerosis
pharmaceutical compositions
related conditions
nicotinic acid
Prior art date
Application number
MEP-601/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Kang Cheng
M Gerard Waters
Kathleen M Metters
Gary O'neill
Original Assignee
Merck Sharp & Dohme
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP60108(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme, Merck Frosst Canada Ltd filed Critical Merck Sharp & Dohme
Publication of MEP60108A publication Critical patent/MEP60108A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
MEP-601/08A 2003-05-15 2004-05-13 Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions MEP60108A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47066503P 2003-05-15 2003-05-15
PCT/US2004/014980 WO2004103370A1 (en) 2003-05-15 2004-05-13 Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MEP60108A true MEP60108A (en) 2011-05-10

Family

ID=33476734

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-601/08A MEP60108A (en) 2003-05-15 2004-05-13 Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions

Country Status (45)

Country Link
US (4) US20040229844A1 (xx)
EP (3) EP1624871B1 (xx)
JP (2) JP4637833B2 (xx)
KR (2) KR100960749B1 (xx)
CN (3) CN101559227B (xx)
AR (1) AR041089A1 (xx)
AU (2) AU2004240597B2 (xx)
BR (1) BRPI0410273A (xx)
CA (1) CA2525772C (xx)
CL (1) CL2004001056A1 (xx)
CO (1) CO5630034A2 (xx)
CR (2) CR8047A (xx)
CY (2) CY1109476T1 (xx)
DE (1) DE602004022036D1 (xx)
DK (2) DK2116244T3 (xx)
DO (1) DOP2004000907A (xx)
EA (2) EA011895B1 (xx)
EC (1) ECSP056156A (xx)
ES (2) ES2328148T3 (xx)
GE (2) GEP20105025B (xx)
GT (1) GT200400098A (xx)
HK (1) HK1092722A1 (xx)
HN (1) HN2004000171A (xx)
HR (2) HRP20090424T1 (xx)
IL (1) IL171962A (xx)
IS (1) IS2708B (xx)
JO (1) JO2564B1 (xx)
MA (1) MA27835A1 (xx)
ME (1) MEP60108A (xx)
MX (1) MXPA05012272A (xx)
MY (1) MY140639A (xx)
NO (1) NO20055957L (xx)
NZ (2) NZ543399A (xx)
PA (1) PA8603201A1 (xx)
PE (1) PE20050552A1 (xx)
PL (2) PL1624871T3 (xx)
PT (2) PT2116244E (xx)
RS (3) RS52731B (xx)
SG (1) SG153667A1 (xx)
SI (2) SI2116244T1 (xx)
TN (1) TNSN05290A1 (xx)
TW (2) TWI334354B (xx)
UA (1) UA89615C2 (xx)
WO (1) WO2004103370A1 (xx)
ZA (1) ZA200508288B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094830A2 (en) * 2001-05-23 2002-11-28 Merck Frosst Canada & Co. DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
EP1603585A2 (en) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
DK2801354T3 (en) 2004-10-08 2017-05-15 Forward Pharma As Controlled release pharmaceutical compositions comprising a fumaric acid ester
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US8165517B2 (en) * 2005-01-19 2012-04-24 The Trustees Of The University Of Pennsylvania Methods for identifying inhibitors of vascular injury
JP2008530250A (ja) * 2005-02-17 2008-08-07 メルク エンド カムパニー インコーポレーテッド アテローム性動脈硬化症、脂質代謝異常及び関連症状の治療方法
AU2006214286A1 (en) * 2005-02-18 2006-08-24 Arena Pharmaceuticals, Inc. Methods and compositions for the treatment of lipid-associated disorders
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
MX2007014517A (es) * 2005-05-17 2008-02-11 Schering Corp Heterociclos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia.
US20090258862A1 (en) * 2005-08-29 2009-10-15 Colletti Steven L Niacin receptor agonists, compositions containing such compounds and methods of treatment
CA2620864A1 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
EP1940382A2 (en) * 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
AU2006331994A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an H3 antagonist/inverse agonist and an appetite suppressant
US20070161578A1 (en) * 2005-12-21 2007-07-12 Hwa Joyce J Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist
KR20080091814A (ko) * 2006-01-20 2008-10-14 쉐링 코포레이션 지질혈증장애의 치료를 위한 니코틴산 수용체 효능제로서의헤테로사이클
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
CN101528746A (zh) * 2006-09-15 2009-09-09 先灵公司 治疗脂质代谢障碍、疼痛、糖尿病和其它障碍的螺环氮杂环丁酮衍生物
WO2008033465A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
CA2663502A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
CN101559058B (zh) * 2008-04-16 2011-07-20 北京本草天源药物研究院 一种治疗血脂异常的药物组合物
WO2009142731A2 (en) * 2008-05-20 2009-11-26 Cerenis Therapeutics S.A. Niacin and nsaid combination therapy
WO2010030360A1 (en) 2008-09-11 2010-03-18 Arena Pharmaceuticals, Inc. 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
US20110165239A1 (en) * 2008-09-24 2011-07-07 Laman Alani Pharmaceutical compositions of atorvastatin
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
PT2379063E (pt) 2009-01-09 2013-05-03 Forward Pharma As Formulação farmacêutica compreendendo um ou mais ésteres de ácido fumárico numa matriz de erosão
CA2793324A1 (en) 2010-03-16 2011-09-22 Aventis Pharmaceuticals Inc. A substituted pyrimidine as a prostaglandin d2 receptor antagonist
CA2793223A1 (en) 2010-03-16 2011-09-22 Aventis Pharmaceuticals Inc. Substituted pyrimidines as prostaglandin d2 receptor antagonists
US20180021302A1 (en) 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) * 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
DE2857653A1 (de) 1977-09-30 1981-02-05 Rca Corp Einrichtung in einem fernsehsystem
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5021447A (en) * 1986-01-23 1991-06-04 Merck Frosst Canada, Inc. Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
DE69621952T2 (de) 1995-10-31 2003-01-16 Schering Corp., Kenilworth Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel
AU7472896A (en) 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
DE122011000014I1 (de) 1995-12-22 2011-11-03 Kowa Co Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium.
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
ES2336492T3 (es) * 1997-07-31 2010-04-13 Abbott Respiratory Llc Composicion que comprende un inhibidor de hmg.coa y un compuesto de acido nicotinico para tratar la hiperlipidemia.
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
HUP0101110A3 (en) * 1997-10-27 2002-06-28 Reddys Lab Ltd Dr Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
JP3640888B2 (ja) 1998-12-07 2005-04-20 シェーリング コーポレイション アゼチジノンの合成プロセス
WO2000038725A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications
ATE549412T1 (de) 1999-04-05 2012-03-15 Schering Corp Stereoselektive mikrobielle reduktion für die herstellung von 1-(4-fluorophenyl)-3(r)- 3(s)- hydroxy-3-(4-fluorophenyl)propyl) -4(s)-(4-hhydroxyphenyl)-2-azetidinon
AU4343500A (en) 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
BR0109050A (pt) 2000-03-09 2004-04-27 Ono Pharmaceutical Co Derivados de indol, processo para prepapação e uso dos mesmos
US20010047027A1 (en) * 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
JP2002008186A (ja) * 2000-06-23 2002-01-11 Mitsubishi Heavy Ind Ltd 車種識別装置
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP3889563B2 (ja) * 2000-09-13 2007-03-07 三洋電機株式会社 映像信号処理回路
WO2002084298A2 (en) 2001-04-11 2002-10-24 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
WO2002094830A2 (en) 2001-05-23 2002-11-28 Merck Frosst Canada & Co. DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
EP1424335A4 (en) 2001-09-07 2005-11-16 Ono Pharmaceutical Co INDOLE DERIVATIVES
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
KR20040095302A (ko) 2002-03-19 2004-11-12 오노 야꾸힝 고교 가부시키가이샤 카르복실산 화합물 및 그 화합물을 유효 성분으로서함유하는 약제
SG154333A1 (en) * 2002-06-03 2009-08-28 Novartis Ag The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4129960B2 (ja) * 2005-07-01 2008-08-06 タキゲン製造株式会社 ステー

Also Published As

Publication number Publication date
NO20055957L (no) 2006-02-14
US20100076002A1 (en) 2010-03-25
EA200702674A1 (ru) 2008-04-28
RS20120498A1 (en) 2013-08-30
NZ572515A (en) 2010-07-30
SI1624871T1 (sl) 2009-12-31
DOP2004000907A (es) 2004-11-30
CR9808A (es) 2008-07-29
TNSN05290A1 (en) 2007-07-10
KR100806008B1 (ko) 2008-02-26
JP4637833B2 (ja) 2011-02-23
KR20060012617A (ko) 2006-02-08
TWI334354B (en) 2010-12-11
CN102526735A (zh) 2012-07-04
CN100441184C (zh) 2008-12-10
RS20120499A1 (en) 2013-08-30
SI2116244T1 (sl) 2012-12-31
EA011895B1 (ru) 2009-06-30
AU2011200986B2 (en) 2012-11-08
CN101559227B (zh) 2012-03-21
MA27835A1 (fr) 2006-04-03
EA200501817A1 (ru) 2006-06-30
PT1624871E (pt) 2009-09-07
KR20080003470A (ko) 2008-01-07
TWI341199B (en) 2011-05-01
AU2011200986A1 (en) 2011-03-31
GT200400098A (es) 2005-03-03
EP2286816A1 (en) 2011-02-23
AU2004240597B2 (en) 2011-01-06
ES2328148T3 (es) 2009-11-10
EA009744B1 (ru) 2008-04-28
CA2525772C (en) 2011-03-15
UA89615C2 (ru) 2010-02-25
DK2116244T3 (da) 2012-11-26
TW200803844A (en) 2008-01-16
US20090233977A1 (en) 2009-09-17
HN2004000171A (es) 2011-07-11
WO2004103370A1 (en) 2004-12-02
MY140639A (en) 2010-01-15
ZA200508288B (en) 2008-08-27
IS2708B (is) 2011-01-15
HRP20090424T1 (en) 2009-09-30
PL2116244T3 (pl) 2013-01-31
JP2010077151A (ja) 2010-04-08
MXPA05012272A (es) 2006-05-19
IL171962A0 (en) 2006-04-10
CL2004001056A1 (es) 2005-03-28
CY1109476T1 (el) 2014-08-13
EP2116244A1 (en) 2009-11-11
ES2392743T3 (es) 2012-12-13
DK1624871T3 (da) 2009-11-16
JO2564B1 (en) 2010-11-03
CO5630034A2 (es) 2006-04-28
IL171962A (en) 2012-06-28
IS8071A (is) 2005-10-13
RS20050777A (sr) 2008-04-04
PT2116244E (pt) 2012-11-02
DE602004022036D1 (de) 2009-08-27
HRP20120818T1 (hr) 2012-11-30
US20040229844A1 (en) 2004-11-18
CY1113342T1 (el) 2016-06-22
GEP20105025B (en) 2010-06-25
SG153667A1 (en) 2009-07-29
CN1787819A (zh) 2006-06-14
EP1624871A1 (en) 2006-02-15
KR100960749B1 (ko) 2010-06-01
AU2004240597A1 (en) 2004-12-02
ECSP056156A (es) 2006-04-19
CR8047A (es) 2006-07-14
CA2525772A1 (en) 2004-12-02
TW200503757A (en) 2005-02-01
CN101559227A (zh) 2009-10-21
BRPI0410273A (pt) 2006-05-16
RS52731B (sr) 2013-08-30
PL1624871T3 (pl) 2009-12-31
EP1624871B1 (en) 2009-07-15
PE20050552A1 (es) 2005-08-06
JP2006526030A (ja) 2006-11-16
US20110118292A1 (en) 2011-05-19
AR041089A1 (es) 2005-05-04
NZ543399A (en) 2009-02-28
HK1092722A1 (en) 2007-02-16
EP2116244B1 (en) 2012-08-08
GEP20084569B (en) 2008-12-25
PA8603201A1 (es) 2005-02-04

Similar Documents

Publication Publication Date Title
MEP60108A (en) Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions
ATE442847T1 (de) Benzimidazol-derivate als mek-hemmer
PL378107A1 (pl) 1,2,4-triazyny hamujące HIV
HUP0300563A3 (en) Inhibitors of dipeptidyl peptidase iv, pharmaceutical compositions containing them and their use
TW200638935A (en) Pyridazine derivatives and their use as therapeutic agents
MEP53708A (en) 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl) -n-methyl -amino) -anilino)-1- phenyl-methylene] -6-methoxycarbonyl -2-indolinone -monoethanesulphonate and the use thereof as a pharmaceutical composition
UA95199C2 (xx) Водна композиція 3-(6-(1-(2,2-дифторбензо$d]$1,3]діоксол-5-іл)циклопропанкарбоксамідо)-3-метилпіридин-2-іл)бензойної кислоти$водная композиция 3-(6-(1-(2,2-дифторбензо$d]$1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
CR9056A (es) Composiciones que contienen piperacilina, tazobactam y un acido aminocarboxilico en un diluyente de lactato de sodio
SG148178A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
HRP20050663A2 (en) Malonamide derivatives as gamma-secretase inhibitors
HRP20050123B8 (hr) Kompozicija i antivirusna aktivnost supstituiranih azaindoloksooctenih piperazin derivata
MY135609A (en) Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
ME00546B (me) Korišćenje inhibitora il-18
MA30620B1 (fr) Carboxamides substitues
RS54140B1 (en) USE OF 24-ORDER
MX2008015250A (es) Sales de acido clorhidrico de la 6-metoxi-8-[4-(1-(5-fluoro)-quino lin-8-il-piperidin-4-il)-piperazin-1-il]-quinolina.
HRP20080452T3 (en) Orally disintegrating pharmaceutical composition comprising risperidone
ME00549B (me) Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja
GEP20074183B (en) Indazole having analgesic activity
TW200716114A (en) Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
MXPA05007483A (es) Derivados de diarilmetilidina piperidina, preparacion y uso de los mismos.
JP2004002473A5 (xx)
MXPA05012117A (es) Derivados de diarilmetiliden piperidina, preparaciones de los mismos y usos de los mismos.
EP1591123A4 (en) USE OF NARINGENINE, NARINGIN AND THEIR SALTS AS EXPERTS IN THE TREATMENT OF COUGH AND COMPOSITIONS THEREOF
RS50847B (sr) Primena ekstrakta pelargonije u kombinaciji sa trputcem za pripremu leka za lečenje upale ždrela